https://charts.traderzeitung.de/phases/US45828J2024 string(1406) "{"isin":"US45828J2024","name":"Intensity Therapeutics Inc","stock_id_xnas":132475577,"stock_id_xnys":132475578,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.05,"close_at":"2026-09-18 21:58:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.09,"close_at":"2026-09-21 19:19:00","complete":true,"perf_pct":0.9877},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":4.01,"close_at":"2026-09-22 21:59:00","complete":true,"perf_pct":-1.956},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"

Intensity Therapeutics Aktie News & Nachrichten

[WKN: A422SC | Symbol: INTS]

Realtimekurs

Intensity Therapeutics, Inc. operates as biotechnology company which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Intensity Therapeutics gefunden werden.

Intensity Therapeutics Nachrichtenticker öffnen

MT Newswires 15.07.2026 14:16 Uhr

Intensity Therapeutics nimmt die Dosierung in einer Phase-2-Studie für eine experimentelle Krebstherapie in der Schweiz wieder auf

08:15 AM EDT, 07/15/2026 (MT Newswires) -- Intensity Therapeutics (INTS) nahm die Dosierung bei neuen Patienten mit seinem experimentellen Krebsmedika